scispace - formally typeset
N

Nora D. Volkow

Researcher at National Institute on Drug Abuse

Publications -  1038
Citations -  121498

Nora D. Volkow is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Dopamine & Addiction. The author has an hindex of 165, co-authored 958 publications receiving 107463 citations. Previous affiliations of Nora D. Volkow include National Institutes of Health & North Shore University Hospital.

Papers
More filters
Journal ArticleDOI

Depressed Dopamine Activity in Caudate and Preliminary Evidence of Limbic Involvement in Adults With Attention-Deficit/Hyperactivity Disorder

TL;DR: Depressed dopamine activity in caudate and preliminary evidence in limbic regions in adults with ADHD that was associated with inattention and with enhanced reinforcing responses to intravenous methylphenidate suggest that dopamine dysfunction is involved with symptoms of inatt attention but may also contribute to substance abuse comorbidity in ADHD.
Journal ArticleDOI

Inverse Association Between BMI and Prefrontal Metabolic Activity in Healthy Adults

TL;DR: The observed association between higher BMI and lower baseline prefrontal metabolism may underlie the impaired performance reported in healthy obese individuals on some cognitive tests of executive function, and the lack of an association between BMI and brain metabolic activation during cognitive stimulation indicates that BMI does not influence brain glucose utilization during cognitive performance.
Journal ArticleDOI

Overexpression of dopamine D2 receptors reduces alcohol self-administration.

TL;DR: It is shown that increases in DRD2 were associated with marked reductions in alcohol preference, and alcohol intake of ethanol preferring rats, which recovered as theDRD2 returned to baseline levels, suggests that high levels of DRD 2 may be protective against alcohol abuse.
Journal ArticleDOI

Mapping cocaine binding sites in human and baboon brain in vivo.

TL;DR: The feasibility of using [11C]cocaine and PET to map binding sites for cocaine in human brain, to monitor its kinetics, and to characterize its binding mechanism by using appropriate pharmacological challenges is demonstrated.